In vitro assays have shown that dacomitinib is active in gefitinib-sensitive and gefitinib-resistant cells as well as EGFR and HER2 mutated NSCLC cell lines with or without MET amplification. Here, ERBB2 is linked to non-small cell lung carcinoma.